drugset / Trial / NCT01970618

Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD Patients

NCT01970618 ↗

Phase 1 Completed 78 enrolled Respivert Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

RV1162 is a new medicine being developed for possible treatment of smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD). The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of RV1162.

Timeline

Start
2013-10
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject RV1162 Unknown — Inhaled